Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Strongbridge Biopharma stock | $3.055

Own Strongbridge Biopharma stock in just a few minutes.

Fact checked

Strongbridge Biopharma plc is a biotechnology business based in the US. Strongbridge Biopharma shares (SBBP) are listed on the NASDAQ and all prices are listed in US Dollars. Strongbridge Biopharma employs 71 staff and has a trailing 12-month revenue of around USD$28.1 million.

How to buy shares in Strongbridge Biopharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Strongbridge Biopharma. Find the stock by name or ticker symbol: SBBP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Strongbridge Biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.055, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Strongbridge Biopharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Strongbridge Biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Strongbridge Biopharma share price

Use our graph to track the performance of SBBP stocks over time.

Strongbridge Biopharma shares at a glance

Information last updated 2021-01-19.
Latest market closeUSD$3.055
52-week rangeUSD$1.5 - USD$4.44
50-day moving average USD$2.7368
200-day moving average USD$2.8732
Wall St. target priceUSD$8
PE ratio 4.2673
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.621

Buy Strongbridge Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Titan
Titan
$0
Stocks, Bonds
N/A
1%
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Strongbridge Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Strongbridge Biopharma price performance over time

Historical closes compared with the close of $3.055 from 2021-01-11

1 week (2021-01-11) N/A
1 month (2020-12-18) N/A
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Is Strongbridge Biopharma under- or over-valued?

Valuing Strongbridge Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Strongbridge Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Strongbridge Biopharma's P/E ratio

Strongbridge Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Strongbridge Biopharma shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Strongbridge Biopharma financials

Revenue TTM USD$28.1 million
Gross profit TTM USD$17.9 million
Return on assets TTM -23.68%
Return on equity TTM -54.61%
Profit margin -149.8%
Book value $1.115
Market capitalisation USD$199.7 million

TTM: trailing 12 months

Shorting Strongbridge Biopharma shares

There are currently 705,043 Strongbridge Biopharma shares held short by investors – that's known as Strongbridge Biopharma's "short interest". This figure is 15.8% up from 608,835 last month.

There are a few different ways that this level of interest in shorting Strongbridge Biopharma shares can be evaluated.

Strongbridge Biopharma's "short interest ratio" (SIR)

Strongbridge Biopharma's "short interest ratio" (SIR) is the quantity of Strongbridge Biopharma shares currently shorted divided by the average quantity of Strongbridge Biopharma shares traded daily (recently around 371075.26315789). Strongbridge Biopharma's SIR currently stands at 1.9. In other words for every 100,000 Strongbridge Biopharma shares traded daily on the market, roughly 1900 shares are currently held short.

However Strongbridge Biopharma's short interest can also be evaluated against the total number of Strongbridge Biopharma shares, or, against the total number of tradable Strongbridge Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Strongbridge Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Strongbridge Biopharma shares in existence, roughly 10 shares are currently held short) or 0.0118% of the tradable shares (for every 100,000 tradable Strongbridge Biopharma shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Strongbridge Biopharma.

Find out more about how you can short Strongbridge Biopharma stock.

Strongbridge Biopharma share dividends

We're not expecting Strongbridge Biopharma to pay a dividend over the next 12 months.

Strongbridge Biopharma share price volatility

Over the last 12 months, Strongbridge Biopharma's shares have ranged in value from as little as $1.5 up to $4.44. A popular way to gauge a stock's volatility is its "beta".

SBBP.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Strongbridge Biopharma's is 1.9112. This would suggest that Strongbridge Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Strongbridge Biopharma overview

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site